Cellectis S.A. (NASDAQ: CLLS) is experiencing an extraordinary surge in its stock price, soaring by an impressive 192.01% to reach $2.8150. That is also accompanied
On January 10, Cellectis S.A. (CLLS) shared that its licensed partner, Allogene Therapeutics Inc. has announced the removal of the FDA’s hold on its clinical
Alterity Therapeutics Limited (ATHE) stock plunged -10.31% to $2.0 in the pre-market trading after the company announced the approval of a US patent for the
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.